Tremelimumab is currently under clinical development for the treatment of various cancers. In NSCLC patients, tremelimumab has not exhibited any specific benefit as a monotherapy, even though it has a mechanism of action which resembles that of ipilimumab. In clinical trial of phase 2 for metastatic...
曲美木单抗: 一种CTLA4抑制剂药物,由AstraZeneca AB (AstraZeneca AB)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: CTLA4抑制剂(细胞毒性T淋巴细胞相关抗原4抑制剂),治疗领域: 肿瘤,消化系统疾病,呼吸系统疾病,在研适应症: 肝细胞癌,晚期肝细胞癌,转移
In addition, this type of immunotherapy is actively used as a novel treatment option for various cancers. This paper reviews the mechanism of action of Durvalumab and Tremelimumab in prospective randomized trials as a single or combination therapy for cancer and their applicability to different tumor...
Based on its mechanism of action and data from animal studies, IMFINZI can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential ...
Based on findings from animal studies and its mechanism of action, fetal harm may occur when administered to pregnant females Ocular side effects: May be associated with retinal detachment; various grades of visual impairment may occur; if events occur in combination with other immune-mediated advers...
Based on its mechanism of action and data from animal studies, IMFINZI can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of repro...
Based on its mechanism of action and data from animal studies, IMFINZI can cause fetal harm when administered to a pregnant woman. There are no data on the use of IMFINZI in pregnant women. Advise pregnant women of th...
In patients with advanced or recurrent dMMR endometrial cancer in the DUO-E study receiving IMFINZI in combination with carboplatin and paclitaxel followed by IMFINZI as a single-agent (n=44), the most common adverse reactions, including laboratory abnormalities (occurring in >20% of patients) wer...
This allows for the potential to develop an increased understanding of drug mechanism of action(s), as well as potential predictive and prognostic exploration to identify patients who may benefit from specific immuno- therapy combinations. In conclusion, the INDUCE-2 study demonstrated that feladili...
Crystal structures of a variant in complex with both mouse and human CTLA-4 confirmed that it targets an equivalent epitope as ipilimumab. These cross-reactive ipilimumab variants may facilitate improved translatability and future mechanism-of-action studies for anti-CTLA-4 targeting in murine models....